Brokers Issue Forecasts for APRE FY2025 Earnings

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Wedbush issued their FY2025 earnings per share estimates for shares of Aprea Therapeutics in a report released on Tuesday, March 25th. Wedbush analyst R. Driscoll anticipates that the company will earn ($0.78) per share for the year. Wedbush currently has a “Outperform” rating and a $11.00 target price on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($2.55) per share. Wedbush also issued estimates for Aprea Therapeutics’ FY2026 earnings at ($0.58) EPS, FY2027 earnings at $0.31 EPS and FY2028 earnings at $1.12 EPS.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings data on Tuesday, March 25th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.20. The company had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.15 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a report on Wednesday, January 15th.

Aprea Therapeutics Stock Performance

NASDAQ:APRE opened at $2.09 on Friday. The company has a market capitalization of $11.36 million, a price-to-earnings ratio of -0.74 and a beta of 0.82. Aprea Therapeutics has a one year low of $2.09 and a one year high of $6.70. The stock has a 50-day simple moving average of $3.03 and a 200 day simple moving average of $3.23.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Landscape Capital Management L.L.C. acquired a new stake in Aprea Therapeutics during the fourth quarter worth about $116,000. LPL Financial LLC bought a new position in shares of Aprea Therapeutics during the fourth quarter valued at approximately $53,000. BNP Paribas Financial Markets acquired a new stake in shares of Aprea Therapeutics during the 4th quarter worth approximately $43,000. Finally, Stonepine Capital Management LLC lifted its holdings in shares of Aprea Therapeutics by 8.8% in the 4th quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock worth $491,000 after purchasing an additional 12,047 shares during the last quarter. 34.19% of the stock is currently owned by institutional investors.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.